1 / 23

Acquisition of HIV infection in children born to HIV infected mothers

Acquisition of HIV infection in children born to HIV infected mothers. Marie-Louise Newell European Collaborative Study Ghent Group on HIV infection in women and children Institute of Child Health, UCL United Kingdom. HIV infection in pregnant women and their children.

eavan
Télécharger la présentation

Acquisition of HIV infection in children born to HIV infected mothers

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Acquisition of HIV infection in children born to HIV infected mothers Marie-Louise Newell European Collaborative Study Ghent Group on HIV infection in women and children Institute of Child Health, UCL United Kingdom

  2. HIV infection in pregnant women and their children • Epidemiology of vertically-acquired HIV infection • Interventions to prevent acquisition of infection in children • Adverse effects of exposure to ART • Consequences of prevention of MTCT policy decisions • Vertically-acquired HIV infection • Need for ART in children

  3. Size of the problem • Worldwide an estimated 1800 infants acquire HIV infection each day, nearly always through vertical transmission before, during or after delivery • Nearly all live in sub-Saharan Africa where, in several countries with antenatal prevalences of 30% or more, declining trends in infant and child mortality are being reversed UN targets specified in 2001: 20% reduction in newly infected children by 2005 and 50% by 2010

  4. Antenatal prevalence Estimated annual number of births to infected women globally: 2,834,772 • Sub-Saharan Africa: 2,285,372 • Asia: 445,217 • China: 17,369 • Europe: 17,596 • USA: 24,871 • South America: 44,347

  5. Mother-to-child transmission • Without specific interventions, the estimated MTCT rate is 15-40% • Differences between populations are associated with maternal characteristics (HIV RNA viral load, CD4 cell count, clinical disease progression), circumstances around delivery (vaginal delivery) and in particular with infant feeding

  6. Prevention of MTCT of HIV-1 • In utero/ intra-partum: • Lowering maternal viral load with ART • Intra-partum: • Avoiding exposure to maternal secretions by elective CS delivery • Per exposure ARV prophylaxis for infant • Post-partum: • Refraining from breastfeeding • Maternal ART to reduce VL • Per exposure ARV prophylaxis for infant

  7. Resource-limited settings • Elective CS and not breastfeeding not feasible, • affordable or safe • Peripartum antiretroviral therapy, mostly ZDV or • sdNVP,substantially and significantly reduces • MTCT risk • Longer (from 28 or 32 weeks gestation) • and/or combination ART • (ZDV+3TC+sdNVP) further reduces • MTCT rates • Revised WHO guidelines (July 2005) suggest • where feasible ZDV from 28 weeks plus sdNVP • and, where possible, 7 days ZDV+3TC for the mother, • and sdNVP plus 7 days ZDV for the infant

  8. Mums-to-be shun HIV tests Malawian health officials are deeply concerned at the reluctance of pregnant women to go for HIV tests, even though those who test positive are given anti-Aids drugs Many men still do not want their wives to be tested.Some pregnant women have resorted to undergoing HIV tests without the knowledge of their husbands, for fear of being abandoned if found positive. "I couldn't tell him because he would have beaten me or even left me" BBC news May 2005

  9. PMTCT programmatic experience • Fewer than 10% of infected women worldwide are estimated to benefit from PMTCT • Even with complete coverage of an effective peripartum ART intervention, an estimated 300,000 children will acquire infection through breastfeeding

  10. Potential consequences of changes in antenatal prevalence, PMTCT coverage or breastfeeding on the annual number of vertical infections 33% 42% 33% Newell, Unicef et al 2005

  11. Adverse events possibly associated with ART during pregnancy and early life are as yet inadequately quantified Antenatal ART can thus substantially and dramatically reduce the risk of MTCT from already infected women and has been a main element in PMTCT programmes worldwide, however evidence from resource-rich countries where ART use is widespread suggests that that benefit may come with a cost

  12. Exposure to HAART from before and early pregnancy: complications and outcome • Risk of premature deliveryECS, AIDS 2004; 18: 2337-2339 • Associated increased perinatal and neonatal mortality • ART-associated mitochondrial abnormalities with clinical symptoms in a small number of uninfected exposed children in the first 18 months of life remain a cause for concern

  13. Haematological effects of ART exposure • Decreased neutrophil levels following in utero and neonatal exposure to ART prophylaxis in uninfected children until at least 8 years of age – clinical implications are not yet clarified (le Chenadec, AIDS 2003, ECS AIDS 2004) ART exposure in fetal or early neonatal life has also been associated with reduced totallymphocyte levels, but not with risk of lymphopenia, until at least 8 years of age, with evidence of a duration and intensity of ART exposure effect

  14. ART could potentially cause medium to long-term adverse events in the large number of uninfected children born to HIV infected mothers These events are likely to be rare, may be sub-clinical and difficult to detect and may not present until later life HAART initiated before or in early pregnancy may be associated with adverse pregnancy outcome Use of ART in PMTCT may also have adverse effects for the mother: drug resistance*, especially following single dose NVP or other monotherapy, may jeopardise future treatment options * See TuPe 5.2 P15

  15. Children with vertically-acquired HIV infection in resource-poor countries Morbidity Mortality Treatment

  16. Aids 'kills one in three' In six sub-Saharan Africa AIDS is contributing to one- to two- thirds of all under five deaths: Botswana, Lesotho, South Africa, Namibia, Swaziland and Zimbabwe The high death rates due to HIV/AIDS highlight the urgency to accelerate the implementation of the comprehensive plan for the treatment and prevention of HIV and AIDS MRC South Africa April 2005

  17. Mortality in children born to HIV infected mothers • Mortality in children under 5 years of age is approximately three times higher in children of HIV infected than of uninfected mothers • HIV negative children born to HIV infected mothers have higher morbidity and mortality than infants born to uninfected mothers • Deaths of HIV infected, but not of HIV uninfected mothers or of fathers, has been associated with increased child mortality

  18. Child survival in settings with a high HIV prevalence • In a pooled analysis based on individual data from seven RCT evaluating interventions to reduce MTCT in sub-Saharan Africa where prolonged breastfeeding is the norm, 3500 children were included, of which nearly 700 were infected • About 5%ofuninfectedand35%ofinfectedchildren willdiebefore age one year,and7.5%and52.5% by two years of age • Uninfected and infected children whose mother had died were 2 - 3.5 times more likely to die than those whose mothers survived Newell et al, Lancet 2004

  19. Estimated progression to serious disease or death by period of birth Children born after 1998 Children born 1994-1998 Children born before 1994 Progression to AIDS or death at one year of age: ≈ 20% pre-1994 (no ART) 10% 1994-1998 (mono or dual therapy) 0% post-1998 (HAART) ECS, unpublished 2005 ECS, unpublished 2005

  20. Paediatric ART eligibility criteria • WHO stage 4 • WHO stage 3: all children under 18 mths; for children over 18 months treat with CD4 guidance especially for TB, LIP, OHL and thrombocytopenia • WHO stages 1 and 2 only with evidence of severe immunological disease progression (on the basis CD4% or TLC) • Children < 18 mths in whom an HIV diagnosis has not yet been confirmed – start treatment on a presumptive diagnosis of stage 4 disease • Co-trimoxazole prophylaxis WHO, July 2005

  21. Delivery of ART for children • Globally, UNAIDS/WHO/UNICEF estimates that 660,000 children less than 15 years of age are eligible for ART on clinical grounds (600,000 in sub-Saharan Africa) • This includes 270,000 infants less than 18 months • An estimated 4 million children should receive cotrimoxazole prophylaxis, early diagnosis allowing cessation in children who are uninfected would reduce this to 2.1m Boerma et al, 2005

  22. Effect of Cotrimoxazole and ART availability on the number of vertically-infected children eligible for ART Newell et al 2005

  23. Concluding remarks HIV infection in women • Prevention of infection in women of child-bearing ages should be high priority in all programmes • Little or no counselling for women who are negative in pregnancy • PMTCT: VCT barriers and only partial uptake of even simple interventions • ART for PMTCT may impact on future therapy options • ART for infected children – finally getting the attention it deserves PMTCT Infected children

More Related